Description
Background & Connection to #566
Issue #566 ("Out-of-sample peptide fold-in and patient biopsy projection for pan-cancer reference atlases and longitudinal clinical trials", Milestone: CPTAC study with DDMC) proposes extending DDMC from a single-cohort transductive clustering algorithm into a reference-to-query transfer learning framework for clinical cancer phosphoproteomics.
Following the completion of core algorithmic prerequisites—e-means mini-batch EMA scaling (#568), out-of-sample peptide fold-in DDMC.fold_in() and bi-cross-validation (#569), expansion of the PSPL atlas to 404 human kinases (#570), exact observed-only diagonal Gaussian marginalization and simulate_dropout() (#571), and flanking PTM crosstalk tokens (#572)—this issue specifies the exact public datasets, data scales, file sizes, download endpoints, verified clinical/genomic/immune annotations, testable hypotheses, and proposed computational approach for the study.
Clinical Use Case & Central Hypothesis
Clinical Problem
In precision oncology, actionable signaling states (target kinase hyperactivation, adaptive bypass rewiring under targeted therapy, and immune-evasive tumor microenvironment states) are governed by post-translational phosphorylation rather than DNA mutations alone (e.g., "pseudo-HER2+" tumors that lack downstream ERBB2 signaling, or EGFR/KRAS-mutant tumors with divergent bypass pathway activation). However, clinical core-needle biopsies (14G–18G) and microscale/DIA phosphoproteomics workflows suffer from:
-
Small cohort sizes (
$n = 15\text{–}80$ patients) insufficient to de novo learn 30–100 kinase-substrate modules and position-specific scoring matrices (PSSMs) without overfitting. - Severe stochastic and intensity-dependent peptide dropout (50–85% missingness) and batch-specific peptide identification, where single-site phosphopeptide biomarkers frequently drop out in individual patient biopsies.
- Unseen phosphosites detected in a query clinical trialplex that were not present in the discovery cohort's filtered feature intersection.
Central Hypothesis
-
Conserved Kinase-Substrate Module Transfer: A reference
DDMCmodel trained on a deep, harmonized pan-cancer or discovery atlas (>1,000 tumors, >50,000–110,000 phosphosites) learns biologically conserved kinase-substrate clusters defined jointly by sequence recognition motifs ($\mathcal{M}_c$ ) and co-regulated phosphorylation dynamics. -
Sequence-Informed Biopsy Projection: Projecting an out-of-sample patient biopsy onto fixed reference modules (
DDMC.project_samples)—combining overlapping phosphosites (weighted by reference posterior responsibilities$\gamma_{ic}$ and site precisions$\tau_{ic}$ ) with novel biopsy phosphosites folded in via sequence motifs (DDMC.fold_in(..., cols=[]))—recovers accurate patient-level kinase module activities ($\hat{\mu}_{\text{new}, c}$ ) even when 50–85% of phosphosites are missing. -
Superior Clinical Biomarker & Pharmacodynamic Sensitivity: Reference-projected
DDMCmodule signatures outperform (a) single-site phosphopeptide biomarkers, (b) sample-wise KSEA / PTM-SEA enrichment scores, and (c) expression-only dimensionality reduction (seq_weight = 0, PCA/NMF) in predicting somatic driver mutations, immune infiltration, longitudinal target inhibition, and pathological complete response (pCR) across independent cohorts and clinical trials.
Specific Datasets to Use (Verified Scale, File Sizes & Download Locations)
All datasets below are publicly available without embargo via the NCI Proteomic Data Commons (PDC), the CPTAC Pan-Cancer Portal, and the cptac Python API, with verified clinical, genomic, and treatment-outcome annotations.
Summary Table of Datasets
| Tier & Role | Dataset / Study Name | Accession / File ID | Scale (Patients / Samples |
Matrix Download Size (Total Study Size) | Verified Clinical & Molecular Annotations Available |
|---|---|---|---|---|---|
| Tier 1A: Pan-Cancer Reference Atlas (Broad Spectrum Mill) | CPTAC Pan-Cancer Harmonized Phosphoproteome (Geffen et al., Cell 2023) | PDC Pan-Cancer UUID fc771375-c1d2-4533-86c8-3a617f21d331 (Phosphoproteome_Broad_Institute_harmonized_v1.tsv.gz) |
1,119 patient samples BRCA, ccRCC, COAD, GBM, HGSC, HNSCC, LSCC, LUAD, PDAC, UCEC, MB) |
95.29 MB .tsv.gz
|
Paired with Clinical_meta_data_v1.zip (0.74 MB, 1,081 cases, 197–245 cols/cohort) & Mutation_Broad_WashU_union_v1.zip (131.38 MB compressed / 531.32 MB MAF) |
| Tier 1B: Pan-Cancer Reference Atlas (UMich / BCM / Sinai GENCODE v34) | CPTAC Pan-Cancer Resource (Li et al., Cancer Cell 2023) | PDC UUIDs 76378111-b53d-4435-9463-e5c416b9de5e (BCM), 0116b655-2b6a-4d18-a379-98d19be22f89 (UMich), f0c1a635-fedc-4cf2-996e-da8d027b15ee (Sinai) |
1,081 cases (Tumor + Matched Normal) across 10 cohorts; ~25,000–55,000 single-site & multi-site phosphosites per cohort (>100,000 union sites) |
275.67 MB (BCM .zip), 1,643.30 MB (UMich .zip), 1,372.99 MB (Sinai .zip) |
OS/PFS survival, stage, grade, driver mutations, CIBERSORT (22 cell types), xCell (38 scores), ESTIMATE, PROGENy (14 pathways), Hallmark, & pre-computed PTM-SEA |
| Tier 1C: Pan-Cancer Co-Measured PTMs (Crosstalk #572) | CPTAC Pan-Cancer Acetylome & Ubiquitylome | PDC UUIDs 5551b44b-a3c8-4a6c-86e5-48c9e66f74e2 (UMich Acetylome), a6d10e8e-531e-4a38-91fd-964ad968619c (Broad Acetylome), 1951cd08-7a85-4fbd-ba7b-753fe62a6926 (Ubiquitylome) |
5–6 cohorts (BRCA, GBM, LSCC, LUAD, UCEC, MB) overlapping Pan-Cancer phosphoproteome patients |
199.12 MB (UMich Acetyl), 13.31 MB (Broad Acetyl), 33.82 MB (CDAP Ubiquityl) | Same harmonized patient IDs and clinical/mutation tables as Tier 1A/1B |
| Tier 2A: LUAD Discovery & Confirmatory Cross-Cohort Transfer | CPTAC LUAD Discovery (PDC000149, Gillette et al., Cell 2020) & Confirmatory (PDC000490) |
PDC000149 (UUID 8855d018-bdc6-4ea7-a96a-f0c7db78f90c) & PDC000490 (UUID 4d2f2a6c-b2e9-4564-ae73-1868ab5b2f37) |
Discovery: 47,956 phosphosites |
Discovery TSVs: 199.04 MB (69.06 MB site TSV; 231.67 GB raw). Confirmatory TSVs: 225.03 MB (66.88 MB site TSV; 258.72 GB raw) |
EGFR, KRAS, STK11, KEAP1, TP53 mutations, ALK/ROS1/RET fusions, Tumor vs. NAT, Hot/Cold immune labels, stage, smoking, survival |
| Tier 2B: External Multi-Ethnic LUAD Cohorts (ICPC Taiwan) | Academia Sinica Taiwan LUAD100 (PDC000220, Chen et al., Cell 2020) & ICPC-B (PDC000564) |
PDC000220 (UUID ebf7bd08-225c-48c5-8552-caad105168dd) & PDC000564 (UUID 73444b92-19ca-47ad-be93-d4f69818aaf0) |
Phase 1 (PDC000220): 30,866 phosphosites PDC000564): 53,640 phosphosites |
PDC000220 TSVs: 200.76 MB (66.87 MB site TSV). PDC000564 TSVs: 364.89 MB (111.09 MB site TSV) |
Academia Sinica LUAD-100_Clinical.xlsx (0.03 MB, 103 patients EGFR_mut (~85% prevalence, L858R/Exon19del), TP53_mut, Stage, APOBEC_group, smoking, differentiation |
| Tier 2C: Naturally Sparse Clinical LUAD Cohort (NCI APOLLO) | APOLLO LUAD Phosphoproteome (PDC000435 TiO2 & PDC000436 FeNTA; Soltis et al., Cell Rep Med 2022) |
PDC000435 (UUID 3f670550-63c2-4b21-9467-ef9e46932f2b) & PDC000436 (UUID e8f465ac-92f5-4441-a16a-14e612cd4e25); PRIDE PXD036025
|
101 LUAD cases; sparse single-site rollup (949 FeNTA + 105 TiO2 sites; peptide TSVs 2.34 MB + 0.37 MB) | Processed TSVs: 4.57 MB combined (123.40 GB raw per fraction) |
APOLLO_LUAD_clinical_treatment_manifest.tsv (0.01 MB, 84 rows |
| Tier 3A: Longitudinal Anti-HER2 Core-Needle Biopsy Trial | Microscaled Proteogenomics DP1 ERBB2+ Breast Cancer Trial (Satpathy et al., Nat Commun 2020; NCT02267290) |
PDC000326 (Phosphosite UUID 4bd2ea8b-c8de-446a-9f99-f82ad0dc7721; Exp Design UUID de817ae3-0bb2-4979-8bec-6e710c615d8e) |
13,148 phosphosites PDC000328/330) |
Processed TSVs: 27.27 MB (9.60 MB site TSV; 21.53 GB total study) |
Longitudinal timepoint (Pre-treatment vs. 48–72h On-treatment), pathological complete response (pCR vs. non-pCR), true vs. pseudo-ERBB2 amplification |
| Tier 3B: Phase III HER2+ Randomized Neoadjuvant Trial Biopsies | Alliance CALGB 40601 HER2+ Trial (Jaehnig et al., Cell Rep Med 2025; NCT00770809) |
PDC000583 (Phosphosite UUID 1b7f9bac-ce73-4720-b2bf-221f385d6f05; Clinical Table UUID e8abe3fc-2559-4679-bf05-16ee4d15b937) |
8,258 phosphosites |
Processed TSVs: 27.14 MB (7.77 MB site TSV; 27.77 GB total study) |
sample_table_CRMpaper.xlsx (0.02 MB, 75 biopsies Tx (paclitaxel + trastuzumab TH, lapatinib TL, or dual THL), pCR, ER_status, PR_status, PAM50_updated, ERBB2_CNA_logratio, ERBB2_protein, Herceptest_IHC
|
| Tier 3C: Longitudinal TNBC Neoadjuvant Trial Core Biopsies | WashU Phase II TNBC Trial (Anurag et al., Cancer Discov 2022; NCT02124902 / NCT02547987) |
PDC000409 (Site UUID 12b4500b-7296-4e10-a4d9-cd4043e61fee; Metadata UUID 6a1bf6f2-1161-4b42-971c-1550008bd3b3) & PDC000580
|
PDC000409: 10,715 phosphosites C1D3 on docetaxel+carboplatin). PDC000580: 60 baseline TNBC cases
|
PDC000409 TSVs: 34.93 MB (9.74 MB site TSV). PDC000580 TSVs: 85.35 MB (26.51 MB site TSV) |
TNBC_only_metadata_v6.3_forPDC_shankha_27thJune2022.xlsx (0.03 MB, 72 biopsies CollectionEventlabelSimplified (Baseline vs. C1D3), pCR_response, PAM50.Mar2020, average.TC (tumor cellularity) |
| Tier 3D: Targeted Kinase Inhibitor Perturbation & Resistance Series | Beat AML Clinical & FLT3-TKI Resistance (PDC000478, PDC000318–320) + decryptM Dose-Response Atlas (Zecha et al., Science 2023) |
PDC000478 (UUID c04bbb8b-ea8b-45bc-b372-90da3c4f469c), PDC000318/319/320; PRIDE PXD037285 / ProteomicsDB decryptM
|
Beat AML: 25,680 phosphosites decryptM: 31 cancer drugs (10 doses, time-resolved) |
Beat AML TSVs: 109.57 MB (39.67 MB site TSV). decryptM curves: via ProteomicsDB API / Zenodo 10.5281/zenodo.7647751
|
Ex vivo drug sensitivity (IC50/AUC for FLT3, MEK, BCL2, pan-TKIs), FLT3-ITD/NPM1/TP53 status, early vs. late TKI resistance states, dose-response |
Detailed Download Instructions & Programmatic Access
1. Direct Programmatic Download from NCI PDC (Zero-Auth REST + GraphQL API)
Every processed matrix and clinical metadata file listed above can be downloaded directly in Python without authentication using its file_id UUID via the PDC signed-URL endpoint:
import json
import urllib.request
def download_pdc_file(file_id: str, out_path: str) -> None:
"""Resolve a fresh CloudFront signed URL from NCI PDC and download the file."""
api_url = f"https://pdc.cancer.gov/pdcapi/file/signedURLFromUuid/{file_id}"
req = urllib.request.Request(
api_url,
headers={
"User-Agent": "Mozilla/5.0",
"Referer": "https://pdc.cancer.gov/pdc/cptac-pancancer",
},
)
with urllib.request.urlopen(req, timeout=15) as resp:
signed_url = json.loads(resp.read().decode())["data"]
urllib.request.urlretrieve(signed_url, out_path)- CPTAC Pan-Cancer Portal Page: https://pdc.cancer.gov/pdc/cptac-pancancer
- NCI PDC GraphQL Endpoint (for study manifests & clinical tables):
https://pdc.cancer.gov/graphql(queries:getAllUIPancancerFiles,filesPerStudy(pdc_study_id: "..."),clinicalPerStudy(pdc_study_id: "...")).
2. Python cptac Package (PayneLab/cptac)
For per-cancer cohort loading across brca, ccrcc, coad, gbm, hnscc, lscc, luad, ov, pdac, and ucec (supporting bcm, umich, broad, washu, mssm, and harmonized sources):
- Repository: https://github.com/PayneLab/cptac (
pip install cptac) - Key API calls:
cohort.get_phosphoproteomics(source="bcm" | "umich" | "broad"),cohort.get_proteomics(),cohort.get_clinical(source="mssm"),cohort.get_somatic_mutation(source="harmonized").
3. Companion Analysis & Reference Mapping Repositories
- Broad Getz Lab Pan-Cancer PTM Repository: https://github.com/getzlab/CPTAC_PanCan_PTM_2023 (includes
data/reference/RefSeq.20180629_Human_ucsc_hg38_cpdbnr_mito_264contams_553smORFs.fastaandvar_map_full_v4.tsvfor mapping RefSeq/GENCODE v34 site IDs onto 11-mer flanking motifs).
Verification of Clinical Annotations
We inspected the clinical metadata archives directly to ensure all necessary clinical endpoints and covariates are present and non-empty:
-
Clinical_meta_data_v1.zip(0.74 MB, 10 files:BRCA_meta.txt,ccRCC_meta.txt,COAD_meta.txt,GBM_meta.txt,HGSC_meta.txt,HNSCC_meta.txt,LSCC_meta.txt,LUAD_meta.txt,PDAC_meta.txt,UCEC_meta.txt):- 1,081 patients (123 BRCA, 104 ccRCC, 111 COAD, 100 GBM, 94 HGSC, 109 HNSCC, 109 LSCC, 111 LUAD, 106 PDAC, 114 UCEC).
-
Demographics, Pathology & Survival:
idx(Patient ID),Tumor,Normal,Age,Sex,BMI,Tumor_Size_cm,Histologic_Grade,Tumor_necrosis,Path_Stage_pT,Path_Stage_pN,Stage,Tobacco_smoking_history,OS_days,OS_event,PFS_days,PFS_event. -
Somatic Driver Mutations & Genomics: Binary mutation status per cohort (e.g.,
EGFR_mutation,KRAS_mutation,STK11_mutation,KEAP1_mutation,TP53_mutationin LUAD;VHL_mutation,PBRM1_mutation,KDM5C_mutationin ccRCC;KRAS_mutation,TP53_mutationin PDAC;MAP3K1_mutation,GATA3_mutation,PIK3CA_mutationin BRCA) + full MAF inPanCan_Union_Maf_Broad_WashU_v1.1.maf(531.32 MBuncompressed) +WES_purity,WES_ploidy,TMB,MSI_H,POLE,CNV_index_CIN_index, and COSMICMutation_signature_SBS*. -
Immune Deconvolution & Microenvironment:
ESTIMATE_StromalScore,ESTIMATE_ImmuneScore,ESTIMATE_ESTIMATEScore, 22CIBERSORT_*immune cell fractions, and 38xCell_*immune/stroma scores. -
Pre-Computed Baseline Pathway & PTM-SEA Scores (for head-to-head benchmarking): 14
PROGENy_*pathway scores, 50HALLMARK_*ssGSEA scores, andPTM_SEA_KINASE-PSP_*/PTM_SEA_PATH-NP_*/PTM_SEA_PERT-*scores.
-
External LUAD Validation (
PDC000220Academia Sinica LUAD-100_Clinical.xlsx&PDC000435APOLLO_LUAD_clinical_treatment_manifest.tsv):-
Academia Sinica LUAD-100_Clinical.xlsx(Table S1A_clinical_103patient, 103 rows$\times$ 22 cols):ID,Proteome_Batch,Age,Gender,SK_SmokingStatus,Stage,StagingN,PathologyDifferentiation,VisceralPleuralStatus,EGFR_mut(including exact alleleL858R,Exon19del,Other,WT),TP53_mut,APOBEC_enrichment,APOBEC_group,Carcinogen_group. -
APOLLO_LUAD_clinical_treatment_manifest.tsv(84 rows$\times$ 32 cols):case_submitter_id,treatment_intent_type,treatment_type,therapeutic_agents,regimen_or_line_of_therapy,number_of_cycles,reason_treatment_ended.
-
-
Clinical Trial Core-Needle Biopsies (
PDC000326,PDC000583,PDC000409):-
PDC000583(sample_table_CRMpaper.xlsx,TableS2B sample data, 75 biopsies):Core_id,Patient_ID,ER_status,PR_status,Tx(TH,TL,THL),pCR,PAM50_updated,ERBB2_CNA_GISTIC_threshold,ERBB2_CNA_logratio,ERBB2_RNA,ERBB2_protein,Herceptest_IHC. -
PDC000409(TNBC_only_metadata_v6.3_forPDC_shankha_27thJune2022.xlsx, 72 biopsies):PPI(Patient ID),CollectionEventlabelSimplified(Baselinevs.Cycle1Day3),pCR_response,PAM50.Mar2020,average.TC,TC.binary. -
PDC000326(S051_Microscaled_Proteogenomics_Satpathy2020_exp_design.xlsx, 35 clinical cores):Core ID,Patient ID (BCN xxxx),Plex No,TMT channel, paired pre-treatment vs. 48–72h on-treatment core IDs (Psuffix) and clinicalpCRannotations from Satpathy et al., Nat Commun 2020.
-
Proposed Approach & What Will Be Tested
Phase 1: Reference Model Training & DDMC.project_samples Implementation
-
Harmonized 11-mer Sequence Mapping Pipeline (
ddmc/datasets.py):- Add dataset loaders for the CPTAC Pan-Cancer harmonized tables, Taiwan LUAD (
PDC000220/PDC000564), and clinical trial biopsy cohorts (PDC000326,PDC000583,PDC000409) that map RefSeq/GENCODE v34 protein/site identifiers (or flanking 15-mers inphosphosite.tmt*.tsv) toDDMC's length-11 sequence motif representation (preserving flanking PTM tokenss,t,y,kwhere multi-site/acetylome data are available).
- Add dataset loaders for the CPTAC Pan-Cancer harmonized tables, Taiwan LUAD (
-
Out-of-Sample Biopsy Projection (
DDMC.project_samples(p_signal_new, return_var=False)inddmc/clustering.py):- Given a fitted reference
DDMCmodel with$K$ clusters, motif models $\mathcal{M}c$, reference peptide responsibilities $\gamma{ic}$ (for$i \in \mathcal{I}_{\text{ref}}$ ), and per-cluster/per-peptide residual variance estimates$\sigma_c^2$ : - Partition query biopsy peptides
$\mathcal{I}_{\text{new}}$ into:-
Overlapping reference peptides ($\mathcal{I}{\text{overlap}} = \mathcal{I}{\text{new}} \cap \mathcal{I}_{\text{ref}}$): Use the reference posterior responsibilities
$\gamma_{ic}$ (or optionally update$\gamma_{ic}$ when projecting a multi-sample cohort) and reference precision weights$\tau_{ic}$ . -
Novel biopsy peptides ($\mathcal{I}{\text{novel}} = \mathcal{I}{\text{new}} \setminus \mathcal{I}_{\text{ref}}$): Fold in via sequence motifs alone using
self.fold_in(p_signal_novel, cols=[]), yielding sequence-prior responsibilities$\gamma^{\text{seq}}_{ic} \propto \pi_c \exp(w \cdot \log P(S_i \mid \mathcal{M}_c))$ .
-
Overlapping reference peptides ($\mathcal{I}{\text{overlap}} = \mathcal{I}{\text{new}} \cap \mathcal{I}_{\text{ref}}$): Use the reference posterior responsibilities
- Estimate the query biopsy's module activity vector $\hat{\mu}{\text{new}, c}$ and posterior uncertainty $\operatorname{Var}(\hat{\mu}{\text{new}, c})$ for each sample
$j$ and cluster$c$ via responsibility-weighted maximum likelihood over observed sites$i \in \operatorname{obs}(j)$ :
$$\hat{\mu}{\text{new}, cj} = \frac{\sum{i \in \operatorname{obs}(j)} \gamma_{ic} \tau_{ic} X^{\text{new}}{ij}}{\sum{i \in \operatorname{obs}(j)} \gamma_{ic} \tau_{ic}}, \qquad \operatorname{Var}(\hat{\mu}{\text{new}, cj}) = \left(\sum{i \in \operatorname{obs}(j)} \gamma_{ic} \tau_{ic}\right)^{-1}$$
- Given a fitted reference
Phase 2: Specific Hypotheses & Quantitative Tests
Test 1: Cross-Cohort Clinical Biomarker & Driver Mutation Transfer (Discovery $\to$ Confirmatory $\to$ ICPC Taiwan $\to$ APOLLO)
-
Hypothesis: Kinase modules learned on the CPTAC LUAD Discovery cohort (
PDC000149,$n=111$ tumors) or the 1,119-tumor CPTAC Pan-Cancer atlas transfer zero-shot (viaproject_sampleswithout refitting cluster assignments) to independent cohorts (PDC000490Confirmatory LUAD,PDC000220/PDC000564Taiwan LUAD, andPDC000435/436APOLLO LUAD) and remain predictive of somatic driver genotypes (EGFR,KRAS,STK11,KEAP1,TP53,ALK), Tumor vs. NAT status, and immune infiltration (Hot_Cold/ESTIMATE_ImmuneScore) under severe biopsy dropout. -
Experimental Protocol:
- Fit
DDMC($K \in {30, 50, 100}$ ,seq_weightselected via BCV Implement bi-cross-validation for joint DDMC hyperparameter selection (#552) #569) onPDC000149(and on the leave-one-cohort-out Pan-Cancer reference). - Train L1-penalized
LogisticRegressionCVclassifiers on reference module centers$\mu_{cj}$ (extendingddmc/figures/figureMS3.py). - Project held-out patients from
PDC000490,PDC000220, andPDC000435/436usingDDMC.project_samples(), both at native completeness and under simulated biopsy dropout from 0% to 85% viasimulate_dropout(mechanism="mnar")and"block".
- Fit
-
Quantitative Metrics:
- Out-of-sample AUROC and AUPRC vs. dropout fraction (0%–85%), benchmarked against:
- Single-site phosphopeptide LASSO biomarkers,
- Sample-wise KSEA / PTM-SEA enrichment scores (using the 404-kinase PSPL atlas and the pre-computed
PTM_SEA_*columns inClinical_meta_data_v1.zip), - Expression-only GMM/PCA/NMF projection (
seq_weight = 0).
- Out-of-sample AUROC and AUPRC vs. dropout fraction (0%–85%), benchmarked against:
Test 2: Longitudinal Pharmacodynamic Rewiring & Pathological Complete Response (pCR) in Clinical Trial Core-Needle Biopsies
-
Hypothesis: Projecting sparse 14G core-needle biopsies (
PDC000326DP1 anti-HER2 trial,PDC000583CALGB 40601 Phase III anti-HER2 trial, andPDC000409WashU Phase II TNBC trial) onto the CPTAC BRCA / Pan-CancerDDMCreference atlas accurately quantifies on-target kinase suppression (ERBB2/MAPK/PI3K-AKT-mTOR modules at 48–72h on-treatment) and separatespCRresponders from non-responders (No pCR), including identifying "pseudo-HER2+" tumors and compensatory bypass modules (EMT/Notch/WNT/FAK/AURKB). -
Experimental Protocol:
- Fit a reference
DDMCmodel on the CPTAC BRCA (PDC000121) + Pan-Cancer reference atlas (110,274sites) and annotate each cluster's upstream kinases viapredict_upstream_kinases()across the 404-kinase PSPL atlas. - Project the core-needle biopsies from
PDC000326($13,148$ sites$\times 38$ aliquots),PDC000583($8,258$ sites$\times 80$ aliquots), andPDC000409($10,715$ sites$\times 74$ aliquots) onto the reference modules viaproject_samples(). - Compute paired within-patient pharmacodynamic shifts $\Delta \hat{\mu}{c} = \hat{\mu}{c, \text{On-Tx}} - \hat{\mu}_{c, \text{Baseline}}$ in
PDC000326(48–72h post-trastuzumab/pertuzumab) andPDC000409(C1D3vs.Baseline), and baseline module activities inPDC000583acrossTH,TL, andTHLarms.
- Fit a reference
-
Quantitative Metrics:
-
Target & bypass effect size: Paired Wilcoxon signed-rank
$p$ -value and Cohen's$d$ for suppression of ERBB2/EGFR/MAPK/AKT modules at 48–72h inpCRresponders vs. non-responders. -
pCRprediction accuracy: Cross-validated AUROC / AUPRC and Mann-Whitney U$p$ -value for predictingpCRinPDC000583($n=59$ ) andPDC000409($n=58$ ) from projectedDDMCmodule activities vs. single ERBB2/phosphosite levels and PTM-SEA. -
Biopsy sample-efficiency curve: Minimum number of detected phosphosites per biopsy required for
$\hat{\mu}_{\text{new}}$ to maintain$\ge 0.90$ cosine similarity with the full-biopsy module profile, quantifying the gain from folding in novel biopsy peptides viaseq_weight > 0.
-
Target & bypass effect size: Paired Wilcoxon signed-rank
Test 3: Pan-Cancer PTM Crosstalk & Scalability Benchmark
-
Hypothesis: Incorporating co-measured multiply phosphorylated peptides and proximal lysine acetylation (
Acetylome_UMich_GENCODE34_v1.zip/Acetylome_Broad_Institute_harmonized_v1.tsv.gz) using the expanded PTM alphabet (Support modified flanking residues (pS/pT/pY, acK) for PTM crosstalk (#565) #572) improves out-of-sample BCV predictive log-likelihood and separates canonical phospho-primed kinase modules (GSK3A/B,CSNK1/2,PLK1,CDK1/2) across the 1,119-patient Pan-Cancer atlas while fitting in minutes and projecting a new biopsy in$< 1\text{ second}$ . -
Quantitative Metrics:
- BCV held-out MSE and predictive log-likelihood (
score_held_out) on multiply modified vs. singly modified peptides across the Pan-Cancer atlas. - Wall-clock runtime and peak memory to fit
DDMCon the110,274 × 1,119Pan-Cancer matrix ($K = 50\text{–}100$ ) and latency per projected biopsy (< 1 s).
- BCV held-out MSE and predictive log-likelihood (
Activity